Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

Author(s): Massimo Breccia , Giuliana Alimena .

Journal Name: Current Drug Targets

Volume 10 , Issue 6 , 2009

Become EABM
Become Reviewer


Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [530 - 536]
Pages: 7
DOI: 10.2174/138945009788488468
Price: $58

Article Metrics

PDF: 12